Ardea Biosciences to Present Clinical Data on its Lead MEK Inhibitor, RDEA119, at the ASCO–NCI–EORTC 2nd Annual Meeting o...
October 24 2008 - 8:08AM
Business Wire
Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that the
Company will present data from an ongoing Phase 1 study of RDEA119,
its lead mitogen-activated ERK kinase (MEK) inhibitor in
development for the treatment of cancer, at the second annual
meeting on Molecular Markers in Cancer, hosted by the American
Society of Clinical Oncology (ASCO), National Cancer Institute
(NCI), and European Organisation for Research and Treatment of
Cancer (EORTC) at the Westin Diplomat Resort & Spa in
Hollywood, FL. Presentation details are as follows: Date/Time: �
Friday, October 31, 2008 from 12:30 p.m. to 2:00 p.m. EDT Session
Title: General Poster Session B Poster Title: The Effect of MEK
Inhibitor RDEA119 on Biomarkers in Advanced Cancer Patients in a
Phase 1 Clinical Trial Poster Number: A15 � About RDEA119 RDEA119,
a non-ATP competitive, highly-selective MEK inhibitor in
development for the treatment of cancer, is the Company's lead
compound from its MEK inhibitor research and development program.
RDEA119 has shown potential as a potent inhibitor of MEK, which is
believed to play an important role in cancer cell proliferation,
apoptosis and metastasis. Preclinical and clinical results suggest
that RDEA119 has favorable properties, including oral dosing and
limited retention in the brain, which, in turn, may result in a
reduced risk of central nervous system (CNS) side effects. About
Ardea Biosciences, Inc. Ardea Biosciences, Inc., of San Diego,
California, is a biotechnology company focused on the discovery and
development of small-molecule therapeutics for the treatment of
HIV, gout, cancer and inflammatory diseases. We have five product
candidates in clinical trials and others in preclinical development
and discovery. Our most advanced product candidate is RDEA806, a
non-nucleoside reverse transcriptase inhibitor (NNRTI), which has
successfully completed a Phase 2a study for the treatment of
patients with HIV. We have evaluated our second-generation NNRTI
for the treatment of HIV, RDEA427, in a human micro-dose
pharmacokinetic study and have selected it for clinical
development. RDEA594, our lead product candidate for the treatment
of hyperuricemia and gout, is being evaluated in a Phase 1 clinical
trial and is believed to be an inhibitor of the URAT1 transporter
in the kidney, which is responsible for regulation of uric acid
levels. We are evaluating our lead MEK inhibitor, RDEA119, in a
Phase 1/2 study in combination with sorafenib (Nexavar�, Onyx
Pharmaceuticals, Bayer HealthCare) and as a single agent in a Phase
1 study, both in advanced cancer patients, and have completed a
Phase 1 study in normal healthy volunteers as a precursor to trials
in patients with inflammatory diseases. Lastly, we have evaluated
our second-generation MEK inhibitor for the treatment of cancer and
inflammatory diseases, RDEA436, in a human micro-dose
pharmacokinetic study and have selected it for clinical
development. Statements contained in this press release regarding
matters that are not historical facts are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
our plans and goals, the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other
compounds, and the timing and results of our preclinical, clinical
and other studies. Risks that contribute to the uncertain nature of
the forward-looking statements include risks related to the outcome
of preclinical and clinical studies, risks related to regulatory
approvals, delays in commencement of preclinical and clinical
studies, costs associated with our drug discovery and development
programs, and risks related to the outcome of our business
development activities. These and other risks and uncertainties are
described more fully in our most recently filed SEC documents,
including our Annual Report on Form 10-K and our Quarterly Reports
on Form 10-Q, under the headings "Risk Factors." All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Oct 2023 to Oct 2024